These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9488718)

  • 21. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotection by (-)-deprenyl and related compounds.
    Maruyama W; Naoi M
    Mech Ageing Dev; 1999 Nov; 111(2-3):189-200. PubMed ID: 10656536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling.
    Tatton WG; Chalmers-Redman RM; Elstner M; Leesch W; Jagodzinski FB; Stupak DP; Sugrue MM; Tatton NA
    J Neural Transm Suppl; 2000; (60):77-100. PubMed ID: 11205159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
    Lai CT; Yu PH
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):186-91. PubMed ID: 9007048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
    Sanz E; Romera M; Bellik L; Marco JI; Unzeta M
    Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.
    Maruyama W; Yamamoto T; Kitani K; Carrillo MC; Youdim M; Naoi M
    Mech Ageing Dev; 2000 Jul; 116(2-3):181-91. PubMed ID: 10996018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
    Suuronen T; Kolehmainen P; Salminen A
    Biochem Pharmacol; 2000 Jun; 59(12):1589-95. PubMed ID: 10799657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells.
    Kusner LL; Sarthy VP; Mohr S
    Invest Ophthalmol Vis Sci; 2004 May; 45(5):1553-61. PubMed ID: 15111614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 32. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
    Olanow CW
    J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium.
    Paterson IA; Zhang D; Warrington RC; Boulton AA
    J Neurochem; 1998 Feb; 70(2):515-23. PubMed ID: 9453545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of short-term administration of (-)-deprenyl and isatin on the expressions of some genes in the mouse brain cortex.
    Fedchenko V; Globa A; Kaloshin A; Kapitsa I; Nerobkova L; Val'dman E; Buneeva O; Glover V; Medvedev A
    Med Sci Monit; 2008 Dec; 14(12):BR269-73. PubMed ID: 19043360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.
    Maruyama W; Takahashi T; Youdim M; Naoi M
    J Neural Transm (Vienna); 2002 Apr; 109(4):467-81. PubMed ID: 11956966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future of neuroprotection in Parkinson's disease.
    Naoi M; Maruyama W
    Parkinsonism Relat Disord; 2001 Oct; 8(2):139-45. PubMed ID: 11489679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
    Magyar K; Szende B; Lengyel J; Tekes K
    J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk.
    Xiao H; Lv F; Xu W; Zhang L; Jing P; Cao X
    Toxicology; 2011 Dec; 290(2-3):286-94. PubMed ID: 22019741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 40. The pharmacology of selegiline.
    Magyar K
    Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.